RT Book, Section
A1 Huen, Auris
A2 Kantarjian, Hagop M.
A2 Wolff, Robert A.
A2 Rieber, Alyssa G.
SR Print(0)
ID 1190833319
T1 Cutaneous Lymphomas
T2 The MD Anderson Manual of Medical Oncology, 4e
YR 2022
FD 2022
PB McGraw Hill Education
PP New York, NY
SN 9781260467642
LK hemonc.mhmedical.com/content.aspx?aid=1190833319
RD 2024/04/19
AB KEY  CONCEPTSCutaneous  lymphomas  are  a  heterogenous  group  of  B-  and  T-lymphocyte  infiltration  to  the  skin  with  varying  clinical  behaviors  and  prognoses.Mycosis  fungoides  (MF)  is  the  most  common  subtype  of  cutaneous  T-cell  lymphoma  (CTCL)  with  typical  indolent  course,  but  a  subset  of  patients  can  progress  to  more  advanced  stages  involving  nodal  and  blood  compartments.Sézary  syndrome  (SS)  is  a  leukemic  variant  of  CTCL  with  a  more  aggressive  course.  In  many  patients,  skin  biopsy  is  nondiagnostic  because  it  does  not  reveal  malignant  cells,  and  diagnosis  is  made  by  peripheral  blood  flow  cytometry  or  Sézary  cell  count.The  treatment  of  patients  with  CTCL  is  guided  by  stage  and  distribution  of  the  skin  involvement.  The  initial  treatment  approach  to  skin-limited  disease  is  embodied  by  the  use  of  skin-directed  treatment  modalities.Two  newly  approved  treatment  options  for  patients  with  relapsed  refractory  MF  and  SS  include  brentuximab  vedotin  and  mogamulizumab,  which  target  skin  and  blood  compartments  of  disease,  respectively.Primary  cutaneous  B-cell  lymphomas  should  be  distinguished  from  secondary  metastasis  of  B-cell  lymphoma  to  the  skin  and  are  typically  associated  with  an  indolent  disease  course  and  a  favorable  prognosis.